Thrombospondin-1 triggers cell migration and development of advanced prostate tumors

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Pharmacologic angiogenesis inhibitors face resistance due to increased tumor invasiveness and metastasis.
• Thrombospondin 1 (TSP1) is an endogenous antiangiogenic factor investigated in prostate cancer.
• Prostate carcinomas exhibit active angiogenesis, making them a relevant model for studying TSP1's role.

Purpose of the Study:

• To reevaluate the role of TSP1 in prostate carcinomas.
• To investigate the mechanisms by which TSP1 influences tumor progression, including angiogenesis, cell migration, and hypoxia.
• To determine the clinical relevance of TSP1 expression in prostatectomy specimens.

Main Methods:

• Xenografted tumor models were used to assess TSP1's effects on angiogenesis and tumor development.
• Prostate tumor cell migration assays were performed, investigating the role of CD36.
• Analysis of radical prostatectomy specimens correlated TSP1 expression with tumor invasiveness and recurrence.
• In vivo studies examined the interplay between TSP1, hypoxia, and angiogenesis.

Main Results:

• TSP1 inhibited angiogenesis but paradoxically fostered tumor development and cell migration in xenografts.
• TSP1-induced cell migration required CD36 and was mimicked by a TSP1-derived peptide.
• TSP1 increased tumor hypoxia, which in turn induced TSP1, creating a positive feedback loop.
• Elevated TSP1 expression in radical prostatectomy specimens correlated with tumor invasiveness and PSA relapse risk.

Conclusions:

• TSP1 acts as a potent stimulator of prostate tumor cell migration and invasion.
• The pro-tumorigenic effects of TSP1 are linked to its ability to increase hypoxia, creating a vicious cycle.
• TSP1 expression may serve as a biomarker for predicting prostate cancer recurrence.
• Targeting the TSP1-mediated hypoxic cycle offers a potential therapeutic strategy to limit prostate tumor invasion.